Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00399152
Other study ID # Perifosine 125
Secondary ID
Status Completed
Phase Phase 1
First received November 9, 2006
Last updated February 14, 2014
Start date October 2006
Est. completion date October 2009

Study information

Verified date November 2011
Source AEterna Zentaris
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This study is a Phase I trial in two parts. In part 1, a MTD to the combination of perifosine and sunitinib malate will be determined. In part 2, with the MTD as a starting point, a group of patients will be accrued with the goal of ensuring that they will be able to tolerate at least two courses of therapy, which would make them evaluable for response in a Phase II study.


Description:

This study is a Phase I trial in two parts. In part 1, an MTD to the combination of perifosine and sunitinib malate will be determined. In some previous trials with perifosine and other biologic agents, doses determined in Phase I studies are not as well tolerated in larger groups of patients when response is an endpoint. Thus in part 2, with the MTD as a starting point, a group of patients will be accrued with the goal of ensuring that they will be able to tolerate at least two courses of therapy, which would make them evaluable for response in a Phase II study. As a secondary endpoint, the effects of the combination of perifosine and sunitinib malate will be evaluated for response rate and time to progression. The pharmacokinetics of the combination of the study drugs will be measured.

For the purposes of this study, one cycle of therapy will be defined as 6 weeks. Patients will take one 50 mg tablet of perifosine one to three times a day and sunitinib malate once a day for 4 out of 6 weeks. Patients may need anti-emetics and/or anti-diarrheals. Patients will be evaluated for progression or response at 12-week intervals.

Patients who experience toxicity may continue on treatment with doses delayed or reduced.

All patients should continue therapy unless disease progression is documented on two occasions at least four weeks apart.

Part 1 of this Phase I study will accrue from six to 24 patients depending on the number of dose levels evaluated. Up to six patients will be treated at each dose level. A dose limiting toxicity (DLT) will be defined as:

- Grade 3 or greater non-hematologic toxicity

- Grade 4 hematologic toxicity


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date October 2009
Est. primary completion date December 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients with a histologically or cytologically confirmed diagnosis of renal tumor or GIST are eligible for this protocol. Patients with other solid tumor types must have their cases reviewed by the OCOG medical monitor.

- The physician must believe that the patient's course and the growth rate of the tumor are such that the patient would feel comfortable continuing treatment for 12 weeks even if there is a transient period of modest tumor growth during the first weeks following the initiation of perifosine and sunitinib malate treatment.

- Patients must have a life expectancy of more than 6 months.

- Patients may have received prior sorafenib or sunitinib malate.

- Patients may have measurable or evaluable disease.

- Patients should have a performance status of 0 to 1 according to the ECOG criteria. However, patients with ECOG performance status of 2 may be admitted with approval from the study chairman or medical monitor.

- Patients must have adequate organ and marrow function, unless in the opinion of the treating investigator, the abnormality is related to tumor and the study chairman or medical monitor agree the abnormality is unlikely to affect the safety of perifosine and/or sunitinib use.

- Patients must have recovered from acute toxicity related to prior therapy including surgery or radiotherapy, excluding alopecia.

- Patients must be able to ingest oral medications or to obtain them through a gastrostomy tube.

- Patients must be at least 18 years of age.

- Patients must have ability to understand and the willingness to sign a written informed consent document.

- LVEF greater than or equal to 50%.

Exclusion Criteria:

- Rapidly progressing disease, as defined by progression within 8 weeks of initiation of the previous regimen

- Patients who have had more than three prior systemic therapies, including biologics, are excluded unless prior approval is obtained from the medical monitor

- Patients receiving any other investigational agents or devices

- Patients initiating a treatment for their cancer within the last two months who will be continued concomitantly with perifosine

- History of allergic reactions attributed to compounds of similar chemical or biologic composition to perifosine (miltefosine or edelfosine)

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection and psychiatric illness/social situations that would limit compliance with study requirements

- Patients currently taking strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) AND inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. John's Wort) because of possible pharmacokinetic interactions with sunitinib. Patients who are no longer taking strong CYP3A4 inhibitors and/or inducers are ineligible unless they have discontinued use 4 weeks prior to beginning therapy.

- HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with perifosine.

- Patients with a history of unstable or newly diagnosed angina pectoris, recent myocardial infarction (within 6 months of enrollment), or New York Heart Association class II-IV congestive heart failure

- Female patients who are pregnant or lactating are ineligible. All females of childbearing potential must have a negative serum pregnancy test within 72 hours of treatment. Men and women of childbearing potential must agree to employ adequate contraception to prevent pregnancy while on therapy and for 4 weeks after the completion of treatment.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Perifosine
Perifosine Oral Dose
Sunitinib Malate
Sunitinib oral dose

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
AEterna Zentaris

References & Publications (1)

Preliminary results / Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 26, No 15S (May 20 Supplement), 2008: 14565

Outcome

Type Measure Description Time frame Safety issue
Primary Toxicities every 6 weeks No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03634540 - A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Active, not recruiting NCT00531284 - Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma Phase 1/Phase 2
Recruiting NCT05842044 - NSAID Use After Robotic Partial Nephrectomy Phase 2
Recruiting NCT05387863 - Decision Aid (DA) for Renal Patients N/A
Terminated NCT02669914 - MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors Phase 2
Completed NCT04933604 - LPN in Patients With High-complex Renal Tumors
Withdrawn NCT03390413 - Robot-assisted Surgical Resection vs. Cryoablation of Localised Renal Cancer N/A
Recruiting NCT05119335 - A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma Phase 1/Phase 2
Active, not recruiting NCT03203473 - Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) Phase 2
Suspended NCT04115254 - Stereotactic Magnetic Resonance Guided Radiation Therapy N/A
Enrolling by invitation NCT02609269 - Decipher Genomics Resource for Intelligent Discovery
Completed NCT01444456 - Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia N/A
Terminated NCT01453595 - BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC) Phase 1/Phase 2
Completed NCT02811250 - Stereotactic Radiotherapy for Renal Cancers N/A
Completed NCT00398814 - Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers Phase 1
Completed NCT00458536 - Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF Phase 1/Phase 2
Recruiting NCT03693014 - A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors Phase 2
Completed NCT00418496 - Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma Phase 1
Recruiting NCT06051162 - HPI Effect in Robotic Urological Surgery on AKI N/A